The present invention provides recombinant antibodies that are specific for the TWEAKR (TNFRSF12A, FN14) comprising a mutated Fc region lacking the glycans attached to the conserved N-linked site in the CH2 domains of the Fc region. Agonistic anti-TWEAKR antibodies comprising a mutation in the Fc region at N297 (using Kabat EU numbering) resulting in an aglycosyl antibody have less side effects and an improved toxicity profile compared to antibodies comprising the natural sequence of the Fc region.The antibodies, accordingly, can be used to treat tumors and other disorders and conditions associated with expression of the TWEAKR. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.本發明提供一種特異性針對TWEAKR(TNFRSF12A、FN14)之重組抗體,其包含缺乏附接在Fc區之CH2功能域中保留N-連接位點之聚醣之突變Fc區。在Fc區N297(採用Kabat EU編號)包含突變之促效性抗-TWEAKR抗體所造成之非糖苷基抗體相較於包含Fc區之天然序列之抗體具有較低副作用及改善之毒性型態。因此該等抗體可用於治療腫瘤及其他與TWEAKR之表現相關之疾病及病症。本發明亦提供一種編碼上述抗體之核酸序列、含其之載體、醫藥組成物及附有使用說明書之套組。
